Intestinal Organoids As a Novel Complementary Model to Dissect Inflammatory Bowel Disease
Overview
Authors
Affiliations
Inflammatory bowel diseases (IBDs) include colitis ulcerosa and Crohn's disease, besides the rare microscopic colitis. Both diseases show a long-lasting, relapsing-remitting, or even chronic active course with tremendous impact on quality of life. IBDs frequently cause disability, surgical interventions, and high costs; as in other autoimmune diseases, their prevalent occurrence at an early phase of life raises the burden on health care systems. Unfortunately, our understanding of the pathogenesis is still incomplete and treatment therefore largely focuses on suppressing the resulting excessive inflammation. One obstacle for deciphering the causative processes is the scarcity of models that parallel the development of the disease, since intestinal inflammation is mostly induced artificially; moreover, the intestinal epithelium, which strongly contributes to IBD pathogenesis, is difficult to assess. Recently, the development of intestinal epithelial organoids has overcome many of those problems. Here, we give an overview on the current understanding of the pathogenesis of IBDs with reference to the limitations of previous well-established experimental models. We highlight the advantages and detriments of recent organoid-based experimental setups within the IBD field and suggest possible future applications.
The application of organoids in colorectal diseases.
Liu Y, Wang D, Luan Y, Tao B, Li Q, Feng Q Front Pharmacol. 2024; 15:1412489.
PMID: 38983913 PMC: 11231380. DOI: 10.3389/fphar.2024.1412489.
Csukovich G, Pratscher B, Burgener I Animals (Basel). 2022; 12(18).
PMID: 36139322 PMC: 9495014. DOI: 10.3390/ani12182461.
Lee H, Jung K, Kwon O, Son Y, Choi E, Yu W Gut Microbes. 2022; 14(1):2121580.
PMID: 36130031 PMC: 9519030. DOI: 10.1080/19490976.2022.2121580.
Patient-derived organoids for therapy personalization in inflammatory bowel diseases.
Lucafo M, Muzzo A, Marcuzzi M, Giorio L, Decorti G, Stocco G World J Gastroenterol. 2022; 28(24):2636-2653.
PMID: 35979165 PMC: 9260862. DOI: 10.3748/wjg.v28.i24.2636.
Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy.
Mishra R, Dhawan P, Srivastava A, Singh A World J Stem Cells. 2020; 12(10):1050-1066.
PMID: 33178391 PMC: 7596447. DOI: 10.4252/wjsc.v12.i10.1050.